Artivion Reports Robust Third Quarter Financial Results
Third Quarter Highlights:
In the latest financial report, Artivion, Inc. (NYSE: AORT) showcased remarkable growth during the third quarter of 2025, achieving a revenue of $113.4 million compared to $95.8 million for the same period in 2024. This represents an 18% increase on a GAAP basis and 16% on a non-GAAP constant currency basis.
Additionally, the company reported a net income of $6.5 million, translating to $0.13 per fully diluted share. Non-GAAP net income reached $7.9 million, or $0.16 per fully diluted share. Adjusted EBITDA saw a significant rise of 39%, amounting to $24.6 million, compared to $17.7 million in the previous year.
Artivion also made significant strides in its clinical programs, having enrolled the first patient in the ARTIZEN trial for Arcevo, marking a substantial milestone for the company.
Key Financial Performance Metrics
Artivion's total revenues for the third quarter of 2025 reflect its strong performance, with a comprehensive review highlighting these financial metrics:
- Total revenues: $113.4 million
- Net income: $6.5 million, equating to $0.13 per fully diluted common share
- Non-GAAP net income: $7.9 million, or $0.16 EPS
- Adjusted EBITDA: $24.6 million, a notable increase from the $17.7 million recorded in Q3 2024
Strategic Developments
Artivion's Chairman, President, and CEO, Pat Mackin, expressed pride in the team's performance, underscoring their commitment to enhancing the growth of stent grafts, On-X valves, and preservation services, which all saw impressive year-over-year expansion. Notably, stent grafts experienced a 38% increase, while On-X valves grew by 25%.
Aside from the strong commercial performance, Artivion’s strategic refinancing of existing credit facilities aims to extend their maturity date to 2031, optimizing their interest rates and securing a new $150 million delayed draw term loan facility to enhance liquidity.
Future Financial Outlook for 2025
Looking ahead, Artivion is optimistic about its growth trajectory. The company is raising the midpoint of its full-year revenue guidance, now expecting a constant growth range of 13% to 14%. Revenues are anticipated between $439 to $445 million, an adjustment from the previous projection.
Furthermore, Artivion forecasts adjusted EBITDA growth between 24% and 28% for the full year, indicating solid expectations for operational performance.
About Artivion, Inc.
Artivion, Inc. is a trailblazer in the field of medical devices concentrated on providing innovative solutions for cardiac and vascular surgeons. Headquartered in the United States, the company specializes in crafting state-of-the-art products that aid in the treatment of aortic diseases, including aortic stent grafts and mechanical heart valves. Artivion has a diverse product portfolio and operates in over 100 countries worldwide, continuing to expand its influence in the global medical device market.
Frequently Asked Questions
1. What were Artivion's revenues for the third quarter of 2025?
Artivion reported revenues of $113.4 million, marking an 18% increase from the previous year.
2. Who is the CEO of Artivion, Inc.?
The CEO of Artivion is Pat Mackin, who also serves as the Chairman and President of the company.
3. How much did Artivion increase its adjusted EBITDA in Q3 2025?
Artivion's adjusted EBITDA increased by 39% to reach $24.6 million compared to $17.7 million in Q3 2024.
4. What is the expected revenue growth for Artivion in 2025?
Artivion expects revenue growth between 13% to 14% for the full year 2025.
5. Where is Artivion, Inc. headquartered?
Artivion, Inc. is headquartered in the United States, focusing on innovations in cardiac and vascular surgery.
